Dr Lal PathLabs saw an 8% surge in shares to Rs 2,539.65 on the BSE following a 51% YoY increase in net profit to Rs 86 crore for Q4FY24. Analysts have varying opinions, with Kotak and JM Financial maintaining positive outlooks, while Goldman Sachs remains cautious.
